
Savara (SVRA) Stock Forecast & Price Target
Savara (SVRA) Analyst Ratings
Bulls say
Savara Inc. is advancing its molgramostim nebulizer solution, currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), which has shown improved health-related quality of life and exercise capacity across various patient subgroups. The anticipated adoption of Molbreevi by pulmonologists exceeds current off-label GM-CSF usage, indicating a significant potential for blockbuster sales, and the estimated patient population has increased, thereby enhancing projected worldwide peak sales from approximately $1.2 billion to $1.6 billion. Furthermore, the company's strengthened probability of success for the Biologics License Application (BLA) approval, alongside a favorable safety profile and reduced regulatory uncertainty, positions Savara favorably for early market acceptance and robust financial performance.
Bears say
Savara Inc. faces significant risks that contribute to a negative outlook on its stock, primarily centered around the potential failure to secure regulatory approval for its molgramostim nebulizer solution, which could diminish market opportunities due to competition and pricing concerns. The company is projected to continue incurring net losses until commercialization and possibly through the early stages of product launch, exacerbated by a recent need to resubmit its Biologics License Application (BLA) after an initial rejection, raising uncertainties regarding the integrity of its manufacturing controls. Additionally, the limited market size for autoimmune pulmonary alveolar proteinosis (aPAP), with only an estimated 3,600 confirmed patients, alongside the high pricing of comparable treatments and barriers to insurance coverage, further complicates Savara's revenue potential and overall valuation.
This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.
Savara (SVRA) Analyst Forecast & Price Prediction
Start investing in Savara (SVRA)
Order type
Buy in
Order amount
Est. shares
0 shares